Chloroarenes

Claritin® Launches The Outsideologist Project - A Multi-Year Initiative Encouraging Children To Spend Time Outdoors

Retrieved on: 
Wednesday, May 12, 2021
Chemical compounds, Drugs, Organic compounds, Carbamates, Chloroarenes, Loratadine, Piperidines

b'WHIPPANY, N.J., May 11, 2021 /PRNewswire/ -- Today, Claritin , the #1 doctor recommended allergy OTC brand, announced the launch of The Outsideologist Project, a new, multi-year initiative aimed at encouraging children to spend more time outdoors.

Key Points: 
  • b'WHIPPANY, N.J., May 11, 2021 /PRNewswire/ -- Today, Claritin , the #1 doctor recommended allergy OTC brand, announced the launch of The Outsideologist Project, a new, multi-year initiative aimed at encouraging children to spend more time outdoors.
  • "Time outside is critical for our health and wellbeing, and I look forward to helping other families foster a deeper appreciation for the outdoors.
  • "That is why Claritin launched The Outsideologist Project to help families across the country instill in their kids a lifelong love of the outdoors and better everyday health.
  • "\nFor additional information about The Outsideologist Project or Claritin, visit www.Claritin.com and our social channels.

Claritin® Launches The Outsideologist Project - A Multi-Year Initiative Encouraging Children To Spend Time Outdoors

Retrieved on: 
Tuesday, May 11, 2021
Chemical compounds, Drugs, Organic compounds, Carbamates, Chloroarenes, Loratadine, Piperidines

b'WHIPPANY, N.J., May 11, 2021 /PRNewswire/ -- Today, Claritin , the #1 doctor recommended allergy OTC brand, announced the launch of The Outsideologist Project, a new, multi-year initiative aimed at encouraging children to spend more time outdoors.

Key Points: 
  • b'WHIPPANY, N.J., May 11, 2021 /PRNewswire/ -- Today, Claritin , the #1 doctor recommended allergy OTC brand, announced the launch of The Outsideologist Project, a new, multi-year initiative aimed at encouraging children to spend more time outdoors.
  • "Time outside is critical for our health and wellbeing, and I look forward to helping other families foster a deeper appreciation for the outdoors.
  • "That is why Claritin launched The Outsideologist Project to help families across the country instill in their kids a lifelong love of the outdoors and better everyday health.
  • "\nFor additional information about The Outsideologist Project or Claritin, visit www.Claritin.com and our social channels.

Delic's Acquisition Target, Ketamine Infusion Centers, Announces Proposal to Acquire 2 Additional Clinic Locations

Retrieved on: 
Tuesday, May 11, 2021
Psychoactive drugs, Drugs, Medical specialties, General anesthetics, Arylcyclohexylamines, Chloroarenes, Nicotinic antagonists, Sedatives, Ketamine, Post-traumatic stress disorder, KIC

("DELIC" or "the "Company") (CSE: DELC) (OTCQB: DELFC) a psychedelic wellness platform, is pleased to announce that its acquisition target (under binding letter agreement see news release dated February 4, 2021), Ketamine Infusion Centers ("KIC"), proposes to acquire two (2) additional licensed ketamine clinics in Arizona.

Key Points: 
  • ("DELIC" or "the "Company") (CSE: DELC) (OTCQB: DELFC) a psychedelic wellness platform, is pleased to announce that its acquisition target (under binding letter agreement see news release dated February 4, 2021), Ketamine Infusion Centers ("KIC"), proposes to acquire two (2) additional licensed ketamine clinics in Arizona.
  • "KIC is the leading name in high quality care and incredible outcomes for its patients and this move helps grow that reputation significantly.
  • As a vital part of the Delic platform, KIC will continue to offer wellness and benefits for many people suffering from anxiety, depression and PTSD.
  • Ketamine Infusion Centers unique model and passion to obtain the highest patient outcomes and purely evidence-based practices is a perfect fit in the Delic ecosystem.

Marinus Pharmaceuticals to Provide Business Update and Announce First Quarter 2021 Financial Results on May 13, 2021

Retrieved on: 
Friday, May 7, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical trials, Psychoactive drugs, Drugs, GABAA receptor positive allosteric modulators, Neurochemistry, Ketones, Sedatives, Anticonvulsants, Chloroarenes, Ganaxolone, Antidepressant, Allosteric modulator, Ketamine

b'Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders.

Key Points: 
  • b'Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders.
  • Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, antidepressant and anti-anxiety effects.
  • Ganaxolone is being developed in IV and oral dose forms intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings.
  • The company has initiated a Phase 3 trial in refractory status epilepticus.

Assertio Holdings, Inc. Partners with Cove, a Leading Migraine Telemedicine Platform, To Launch Direct to Patient Digital Campaign to Increase Accessibility of CAMBIA® (diclofenac potassium) and SPRIX® (ketorolac tromethamine)

Retrieved on: 
Wednesday, May 5, 2021
Medical specialties, Hepatotoxins, Nonsteroidal anti-inflammatory drugs, Chloroarenes, Diclofenac, Clinical medicine, Health care, Jaundice, Hepatitis, Liver, Cambia

Different\nformulations of oral diclofenac (e.g., CAMBIA, diclofenac sodium enteric-coated tablets, diclofenac sodium\neven if the milligram strength is the same.

Key Points: 
  • Different\nformulations of oral diclofenac (e.g., CAMBIA, diclofenac sodium enteric-coated tablets, diclofenac sodium\neven if the milligram strength is the same.
  • Postmarketing\nsurveillance has reported cases of severe hepatic reactions, including liver necrosis, jaundice, fulminant\nhepatitis with and without jaundice, and liver failure.
  • If CAMBIA is used in patients with severe heart\nfailure, monitor patients for signs of worsening heart failure.\nnecrosis and other renal injury.
  • These forward-looking statements relate to, among other things, future events or the future performance or operations of Assertio.

NLS Pharmaceutics Announces Patent Issuance in Europe for its Mazindol Controlled-Release Formulation (Mazindol CR)

Retrieved on: 
Wednesday, May 5, 2021
Psychoactive drugs, Amphetamine, Stimulants, Chloroarenes, Imidazolines, Mazindol, Narcolepsy, Attention deficit hyperactivity disorder, Drug

EP3426232, entitled A MAZINDOL IR/SR MULTILAYER TABLET AND ITS USE FOR THE TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD).

Key Points: 
  • EP3426232, entitled A MAZINDOL IR/SR MULTILAYER TABLET AND ITS USE FOR THE TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD).
  • "Earlier this year, we were granted a similar patent in Canada, and our U.S. patent application is pending review.
  • Additionally, this newly issued patent augments the Orphan Drug Designations that we have for Quilience in both Europe and the U.S.
  • The Company\'s lead product candidate, Quilience is a proprietary controlled-release formulation of mazindol (mazindol CR), and is being developed for the treatment of narcolepsy.

Tiziana Announces Strategic Initiative with Takanawa Japan K.K., Pharma Team, to Identify a Partner in Japan and Other Asian Countries for Further Clinical Development of Milciclib in Patients with Advanced Hepatocellular Carcinoma.

Retrieved on: 
Wednesday, May 5, 2021
Aromatic compounds, Tyrosine kinase inhibitor, Organic compounds, Chemical compounds, TKI, Chloroarenes, Aromatic amines, Quinazolines, Protein kinase inhibitors, Lestaurtinib, Matuzumab

The clinical data, presented at the American Society of Clinical Oncology (ASCO)1, demonstrated that the treatment was well-tolerated and produced clinical activity.

Key Points: 
  • The clinical data, presented at the American Society of Clinical Oncology (ASCO)1, demonstrated that the treatment was well-tolerated and produced clinical activity.
  • Recently, a patent covering the use of Milciclib in combination with a tyrosine kinase inhibitor (TKI) or other drugs was granted2.
  • The granted claims provide complete freedom to further develop a combination of Milciclib with an approved TKI for treatment of patients with advanced HCC or other cancers.
  • Takanawa also supports companies entering the Japanese and Asian market as well as Japanese companies to enter overseas markets.

Elanco Animal Health Introduces First Oral Flea and Tick Product for Cats, Credelio® CAT (lotilaner)

Retrieved on: 
Tuesday, May 4, 2021
Health, Consumer, Agriculture, Natural Resources, Pets, Pharmaceutical, Veterinary, Haematophagy, Veterinary drugs, Chloroarenes, Insecticides, Veterinary medicine, Acaricides, Lotilaner, Branches of biology, Flea, Cat, Tick, Health sciences

b'Veterinarians in the U.S. now have a new, innovative option for flea and tick control as Elanco Animal Health Incorporated (NYSE: ELAN) introduces Credelio Cat, the first oral flea and tick product for cats.\nCredelio Cat starts killing fleas on cats within 6 hours.

Key Points: 
  • b'Veterinarians in the U.S. now have a new, innovative option for flea and tick control as Elanco Animal Health Incorporated (NYSE: ELAN) introduces Credelio Cat, the first oral flea and tick product for cats.\nCredelio Cat starts killing fleas on cats within 6 hours.
  • The small, chewable product maintains fast-acting, sustained flea efficacy throughout the month in cats 8 weeks and older.
  • \xe2\x80\x9cIt\xe2\x80\x99s great to have a first-of-its-kind flea and tick option for cat owners who prefer oral administration or want to try something besides a topical.
  • The effectiveness of Credelio CAT against black-legged ticks in kittens less than 6 months of age has not been evaluated.

Champignon Brands Changes Name to Braxia Scientific to Reflect the Integration of Ketamine and Psychedelic Clinics and its Research and Development Priorities

Retrieved on: 
Monday, May 3, 2021
Drugs, Psychoactive drugs, Neurochemistry, Antidepressants, General anesthetics, Arylcyclohexylamines, Chloroarenes, Nicotinic antagonists, Ketamine, Forward-looking statement

The name change reflects the Company\'s commitment to providing access to, and leadership in, setting the standard of care for ketamine treatment in depression through its network of clinics, as well as the Company\'s ketamine and psychedelic derivative research and drug development priorities.

Key Points: 
  • The name change reflects the Company\'s commitment to providing access to, and leadership in, setting the standard of care for ketamine treatment in depression through its network of clinics, as well as the Company\'s ketamine and psychedelic derivative research and drug development priorities.
  • Our goal is to improve the access and quality of mental healthcare service to people affected by these disorders in a highly cost-effective manner.
  • All statements that are not historical facts, future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations, or beliefs of future performance are "forward-looking statements.
  • There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements.\nView original content to download multimedia: http://www.prnewswire.com/news-releases/champignon-brands-changes-name-t...\n'

Melinta Therapeutics and Hikma Sign Exclusive Licensing Agreement for Two Novel Anti-Infectives for the Middle East and North Africa Region

Retrieved on: 
Thursday, April 29, 2021
Biotechnology, Infectious diseases, Other Health, Health, Pharmaceutical, Chemical compounds, Organic compounds, Chemistry, Azetidines, Chloroarenes, Delafloxacin, Pyridines, Antibiotic, XC2, Medication, Melinta Therapeutics, Hikma, MELINTA THERAPEUTICS, HIKMA

This extends Hikma\xe2\x80\x99s existing partnership with Melinta for their intravenous and oral formulations of Baxdela\xc2\xae (delafloxacin), a novel antibiotic product.

Key Points: 
  • This extends Hikma\xe2\x80\x99s existing partnership with Melinta for their intravenous and oral formulations of Baxdela\xc2\xae (delafloxacin), a novel antibiotic product.
  • \xe2\x80\x9cAs one of the leading suppliers in the region, it is our responsibility to equip doctors with the latest and most innovative developments to treat their patients.
  • Visit www.melinta.com for more information.\nHikma helps put better health within reach every day for millions of people around the world.
  • For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them.